Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

Enhertu (trastuzumab deruxtecan) reduced the risk of disease progression or death compared to Kadcyla (trastuzumab emtansine) by 72% in patients with HER2-positive, advanced breast cancer who had ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...

Each of these cancers also has other specific criteria for treatment with Enhertu, including prior treatments received. In brief, the cancers are: HER2-positive breast cancer unresectable or ...

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer. Dr. Debu Tripathy breaks down the FDA approval ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

AZ, Daiichi's Enhertu nabs 7th FDA nod, including in 'HER2-ultralow' use, in breast cancer first Stomach cancer has traditionally been a tough nut for researchers to crack. In 2023, the FDA ...

Breast cancer symptoms or treatment side effects may affect your physical abilities or comfort while doing certain daily activities. But there are steps you can take to manage these challenges.

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LON:AZN) (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in ...